Latest ASX Announcements

ASX announcement: Dimerix raises a further A$4.5M

Dimerix Limited  has raised an additional $4.5 million through the issue of 37,500,000 shares at 12 cents per share to wholesale and institutional clients of Westar Capital and Baker Young Stockbrokers who acted as Joint Lead managers to the Issue.

  • Dimerix raises a further A$4.5 million via a significantly oversubscribed Placement.
  • The Capital Raising was […]
By | 2018-02-21T07:01:16+00:00 February 21st, 2018|Latest ASX Announcements|

Quarterly Review – Q2 FY2018

Quarter highlights

  • DMX-200 Phase 2a in Chronic Kidney Disease sub-group analysis was released in November showing compelling efficacy signals in the Diabetic Nephropathy sub-group.
  • Trial data was presented at the ASN Kidney Week in New Orleans, BIO- Europe in Berlin, the World Congress in Clinical Trials in Diabetes in Berlin and, post quarter, to meetings […]
By | 2018-01-30T08:29:57+00:00 January 30th, 2018|Latest ASX Announcements|

Results of Entitlement Offer

Dimerix Limited or the “Company” (ASX: DXB), a clinical stage biotechnology company today announces results from its 1 for 2 pro-rata non-renounceable Entitlement Offer of fully paid ordinary shares in Dimerix announced on 6 December 2017, opened on 13 December 2017 and closed on 19 January 2018.

View the full release here. 

By | 2018-01-24T06:50:33+00:00 January 24th, 2018|Latest ASX Announcements|

Recorded interview with CEO and rights issue reminder

The Dimerix Limited (ASX: DXB) Entitlement Offer or ‘Rights Issue’ to raise $5.5 million is due to close this Friday, 19 January 2018 at 7:00pm AEDT (Sydney time).

Funds raised are important for the commercialisation of DMX-200 across the Chronic Kidney Disease areas of FSGS and Diabetic Nephropathy

An Entitlement and Acceptance form has been mailed to shareholders, and […]

By | 2018-01-16T07:17:05+00:00 January 16th, 2018|Latest ASX Announcements|

DMX-200 Dosage Optimisation Study Successfully Completed in Preparation for Phase 2b trial

Dimerix Limited announces top-line results from a recent pharmacokinetic (PK) study of an extended release tablet formulation for their DMX-200 program targeting Chronic Kidney Disease (CKD).

The study found a newly formulated extended release tablet of DMX-200 taken twice daily (against three times daily for the previous formulation) increases the duration of release of DMX-200 in […]

By | 2018-01-08T08:19:43+00:00 January 8th, 2018|Latest ASX Announcements|